AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22406028 — intervention group
Group type: EXPERIMENTAL
Intervention: WEI JET (Supraglottic jet ventilation)
Number of subjects: 0
Study 22406028 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube (control group)
Number of subjects: 0
Study 20864606 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills programme 'Eigenständig werden' (Becoming independent)
Number of subjects: 919
Study 20864606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 919
Study 18684077 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC Factor
Number of subjects: 25
Study 15959851 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]d-threo-methylphenidate ([(11)C]dMP) in PD patients
Number of subjects: 36
Study 15959851 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 14509153 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (alliin 22.4 mg/day)
Number of subjects: 33
Study 14509153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10204589 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered whole blood
Number of subjects: 27
Study 10204589 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed red cells
Number of subjects: 27
Study 10204589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transfusions)
Number of subjects: 27
Study 10204589 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 27
Study 7590497 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO) at a dose of 40 mg/kg/day as a 24-hour intravenous infusion from day -9 to day +60
Number of subjects: 15
Study 7590497 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO)
Number of subjects: 15
Study 2671247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional insulin treatment (ICT)
Number of subjects: 95
Study 2671247 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (RT)
Number of subjects: 95
Study 1101904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide 10 mg t.i.d.
Number of subjects: 20
Study 1101904 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixole 0.5 mg t.i.d.
Number of subjects: 20
Study 1101904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide with alcohol (0.5 g/kg)
Number of subjects: 20
Study 1101904 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixole with alcohol (0.5 g/kg)
Number of subjects: 20
Study 30829050 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO-201 (0.2 mL, 12 mg, n = 130)
Number of subjects: 260
Study 30829050 — intervention group
Group type: COMPARATOR
Intervention: Sham (air injection, n = 130)
Number of subjects: 260
Study 30829050 — intervention group
Group type: EXPERIMENTAL
Intervention: OTO-201
Number of subjects: 260
Study 28982378 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 0
Study 28982378 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0
Study 25041226 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise with whole-body vibrations (RVE)
Number of subjects: 26
Study 25041226 — intervention group
Group type: COMPARATOR
Intervention: Resistive exercise (RE)
Number of subjects: 26
Study 24254557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cc 1% lidocaine before biopsy
Number of subjects: 80
Study 24254557 — intervention group
Group type: COMPARATOR
Intervention: Conventional biopsy without local anesthesia
Number of subjects: 80
Study 21270143 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 382
Study 21270143 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic regimen selected by control patient's psychiatrist
Number of subjects: 382
Study 19091331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg selenium orally daily (selenium group of 116)
Number of subjects: 468
Study 19091331 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg N-acetyl-cysteine orally daily (N-acetyl-cysteine group of 118)
Number of subjects: 468
Study 19091331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg selenium plus 600 mg N-acetyl-cysteine orally daily (selenium plus N-acetyl-cysteine group of 116)
Number of subjects: 468
Study 19091331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group of 118)
Number of subjects: 468
Study 17185202 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo Now
Number of subjects: 333
Study 17185202 — intervention group
Group type: COMPARATOR
Intervention: Bridge method
Number of subjects: 333
Study 15546289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 1108
Study 15546289 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 1108
Study 15546289 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stent (long lesions)
Number of subjects: 1108
Study 11310696 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of blood products through central venous catheters
Number of subjects: 0
Study 11310696 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia during catheterization
Number of subjects: 0
Study 11310696 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter insertion under maximal sterile barrier precautions
Number of subjects: 0
Study 9741495 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 142
Study 9741495 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 142
Study 7750678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose-neomycin
Number of subjects: 80
Study 7750678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 IU/kg heparin
Number of subjects: 19
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg heparin
Number of subjects: 19
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU/kg heparin
Number of subjects: 19
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg heparin
Number of subjects: 19
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated daily injections of 75 IU/kg heparin
Number of subjects: 19
Study 3773728 — intervention group
Group type: COMPARATOR
Intervention: Infusion of heparin or saline on three consecutive days
Number of subjects: 19
Study 3773728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subjects over time
Number of subjects: 19
Study 29103962 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized human corneal stromal lamina alone
Number of subjects: 9
Study 29103962 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized human corneal stromal lamina with autologous adipose‐derived adult stem cell recellularization
Number of subjects: 9
Study 26963689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Number of subjects: 181
Study 26963689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Number of subjects: 181
Study 26963689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (among participants with Trail Making Test scaled score of 7 or higher)
Number of subjects: 181
Study 26963689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among participants with Trail Making Test scaled score of 7 or higher)
Number of subjects: 181
Study 26963689 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole and Placebo (among participants with Trail Making Test scaled score of less than 7)
Number of subjects: 181
Study 26963689 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 181
Study 25440887 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2737
Study 25440887 — intervention group
Group type: COMPARATOR
Intervention: DP-SES
Number of subjects: 2737
Study 22831805 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 57
Study 22831805 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 57
Study 20386995 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for osteoarthritis
Number of subjects: 0
Study 20386995 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for chronic neuropathic pain
Number of subjects: 0
Study 20386995 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for ADHD
Number of subjects: 0
Study 18469572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 800 microg
Number of subjects: 8
Study 18469572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 microg
Number of subjects: 8
Study 18469572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 200 microg
Number of subjects: 8
Study 18469572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (all doses)
Number of subjects: 8
Study 18320340 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term desmopressin (0.2 mg for first 3 weeks, 0.4 mg for following 3 weeks) plus 12 weeks of enuretic alarm therapy
Number of subjects: 58
Study 18320340 — intervention group
Group type: COMPARATOR
Intervention: Enuretic alarm therapy alone for 12 weeks
Number of subjects: 58
Study 18320340 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term desmopressin plus alarm therapy
Number of subjects: 58
Study 15029120 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with sumamed
Number of subjects: 245
Study 15029120 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with rulid
Number of subjects: 245
Study 15029120 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with clindamycin
Number of subjects: 245
Study 11391325 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral RT-PCR positive for picornavirus and parainfluenza
Number of subjects: 495
Study 11391325 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral RT-PCR positive
Number of subjects: 495
Study 11391325 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born during winter and summer months
Number of subjects: 495
Study 9430184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (Aredia)
Number of subjects: 0
Study 8305102 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscope-guided surgery
Number of subjects: 73
Study 8305102 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 73
Study 3520383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 23
Study 3520383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31682461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched-polyunsaturated fat hypocaloric diet (diet P)
Number of subjects: 360
Study 31682461 — intervention group
Group type: COMPARATOR
Intervention: Enriched-monounsaturated fat hypocaloric diet (diet M)
Number of subjects: 360
Study 28000174 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS + Gelatin Tannate
Number of subjects: 60
Study 28000174 — intervention group
Group type: COMPARATOR
Intervention: ORS
Number of subjects: 60
Study 25015782 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 352
Study 25015782 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 352
Study 25015782 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 352
Study 24734423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (mature infants)
Number of subjects: 94
Study 24734423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (premature infants)
Number of subjects: 94
Study 24734423 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (mature infants)
Number of subjects: 94
Study 24734423 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (premature infants)
Number of subjects: 94
Study 21788265 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term practice group (60 hours of rehabilitation over 16 months with bilateral arm movements and active neuromuscular stimulation)
Number of subjects: 18
Study 21788265 — intervention group
Group type: COMPARATOR
Intervention: Short-term practice group (1 treatment protocol over 4 weeks)
Number of subjects: 18
Study 19326288 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg prolonged-release preparation, CircadinTM)
Number of subjects: 0
Study 19326288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 0
Study 19326288 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 16769957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP)
Number of subjects: 19
Study 16769957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15619134 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (130 mg twice daily for 3 days)
Number of subjects: 24
Study 11703885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 10
Study 11703885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg extended-release daily
Number of subjects: 10
Study 11703885 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (various doses)
Number of subjects: 10
Study 11703885 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 5 mg tid
Number of subjects: 10
Study 9219047 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 10
Study 9219047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (20 mg)
Number of subjects: 10
Study 9219047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9219047 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and dextroamphetamine
Number of subjects: 10
Study 9219047 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 10
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction followed by desflurane and nitrous oxide (Group 1)
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction followed by propofol infusion and nitrous oxide (Group 2)
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and nitrous oxide induction and maintenance (Group 3)
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane induction and maintenance (Group 4)
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate recovery in Group 4
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor function test results
Number of subjects: 60
Study 8484548 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative narcotic requirement
Number of subjects: 60
Study 3547179 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacereine (100 mg/die for 4 weeks)
Number of subjects: 71
Study 3547179 — intervention group
Group type: COMPARATOR
Intervention: Diacereine (100 mg/die for 2 weeks)
Number of subjects: 71
Study 3547179 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacereine (100 mg/die 5 days a week for 12 weeks)
Number of subjects: 71
Study 30047584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 16
Study 30047584 — intervention group
Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 16
Study 27531238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid of intracavitary and interstitial brachytherapy (HBT) with 30‐30.6 Gy in 15‐17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m(2)), followed by 24 Gy in 4 fractions of HBT and central shield EBRT up to 50‐50.4 Gy in 25‐28 fractions.
Number of subjects: 55
Study 27531238 — intervention group
Group type: COMPARATOR
Intervention: HBT
Number of subjects: 55
Study 24749664 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-week online intervention for hearing-aid users
Number of subjects: 76
Study 24749664 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 76
Study 22898744 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate extinction of non-masked conditioned stimuli (CS)
Number of subjects: 0
Study 22898744 — intervention group
Group type: COMPARATOR
Intervention: Delayed extinction
Number of subjects: 0
Study 20459918 — intervention group
Group type: EXPERIMENTAL
Intervention: Water‐pipe smoking
Number of subjects: 30
Study 20459918 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 30
Study 18655753 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline 0.1% (n = 29)
Number of subjects: 61
Study 18655753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution; n = 32)
Number of subjects: 61
Study 16428155 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine once daily for 2 weeks
Number of subjects: 80
Study 16428155 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole twice daily for 4 weeks
Number of subjects: 80
Study 12114432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1250 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 56
Study 12114432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus Gemcitabine (Gem)
Number of subjects: 56
Study 12114432 — intervention group
Group type: EXPERIMENTAL
Intervention: High ERCC1 mRNA levels
Number of subjects: 56
Study 10459515 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with attached cumulus tissue
Number of subjects: 247
Study 10459515 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture with added cumulus tissue
Number of subjects: 247
Study 10459515 — intervention group
Group type: COMPARATOR
Intervention: Culture without cumulus tissue
Number of subjects: 247
Study 7850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16
Study 7850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 16
Study 7850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16
Study 7850941 — intervention group
Group type: COMPARATOR
Intervention: Control (predrug)
Number of subjects: 16
Study 2351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropin tablets
Number of subjects: 8
Study 2351364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 385518 — intervention group
Group type: EXPERIMENTAL
Intervention: V. F. (peptides from bovine Factor VIII) administered at 1 mg/day in two oral doses
Number of subjects: 0
Study 385518 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30767422 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention consisting of in-service training, mentoring and supportive supervision, infrastructure support, and peer outreach.
Number of subjects: 12
Study 30767422 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 12
Study 30767422 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 facilities and their catchment areas)
Number of subjects: 12
Study 27340950 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-Tac
Number of subjects: 30
Study 27340950 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 30
Study 27340950 — intervention group
Group type: COMPARATOR
Intervention: ER-Tac
Number of subjects: 30
Study 25500935 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Cortef (glucocorticoids) administered orally in the late afternoon for 6 days
Number of subjects: 0
Study 22890582 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (Livact group, n = 26)
Number of subjects: 56
Study 22890582 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (Control group, n = 30)
Number of subjects: 56
Study 21376536 — intervention group
Group type: COMPARATOR
Intervention: Bilateral TMJ prosthesis
Number of subjects: 18
Study 21376536 — intervention group
Group type: COMPARATOR
Intervention: Unilateral TMJ prosthesis
Number of subjects: 18
Study 21376536 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal controls
Number of subjects: 18
Study 19446989 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in the right leg
Number of subjects: 306
Study 19446989 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in the left leg
Number of subjects: 306
Study 19446989 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in both legs
Number of subjects: 306
Study 19446989 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI <0.9
Number of subjects: 306
Study 17117395 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (titrated to 20 mg)
Number of subjects: 60
Study 17117395 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 15569113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (10, 20, or 40 mg daily)
Number of subjects: 846
Study 15569113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (20 or 40 mg daily)
Number of subjects: 846
Study 15569113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 15569113 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine (150 mg b.d.)
Number of subjects: 846
Study 11699749 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with pronouns and nouns
Number of subjects: 50
Study 11699749 — intervention group
Group type: COMPARATOR
Intervention: Training with full nouns only
Number of subjects: 50
Study 9696445 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (TAPP technique)
Number of subjects: 175
Study 9696445 — intervention group
Group type: COMPARATOR
Intervention: Bassini repair
Number of subjects: 175